Printer Friendly

Microscopic Polyangiitis Therapeutics Pipeline Market H1 2015 Review Report.

RnRMarketResearch.com adds "Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2015" report to its store. The report provides an overview of the microscopic polyangiitis's therapeutic pipeline.

DALLAS, Feb. 13, 2015 /PRNewswire-iReach/ -- The report "Microscopic Polyangiitis (MPA) -- Pipeline Review, H1 2015C[thorn] provides comprehensive information on the therapeutic development for Microscopic Polyangiitis (MPA). Microscopic polyangiitis (MPA) is a type of vasculitis that affects small blood vessels. Microscopic polyangiitis (MPA) is an uncommon disease. The cause of Microscopic polyangiitis (MPA) is unknown. Microscopic polyangiitis (MPA) can occur at any age, but typically affects people in between 50 to 60 years of age. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available @ http://www.rnrmarketresearch.com/microscopic-polyangiitis-mpa-pipeline-review-h1-2015-market-report.html.

Photo - http://photos.prnewswire.com/prnh/20150213/175481

The report also reviews key players involved in the therapeutic development for Microscopic Polyangiitis (MPA) and special features on late-stage and discontinued projects. Companies discussed in this Microscopic Polyangiitis (MPA) -- Pipeline Review, H1 2015 report include Anthera Pharmaceuticals Inc., Aprogen, Inc., ChemoCentryx, Inc., Epirus Biopharmaceuticals, Inc., Hospira, Inc., Panacea Biotec Limited, Sandoz Inc.

Symptoms of Microscopic polyangiitis (MPA) include fatigue, fever, decreased appetite, rapid and sudden weight loss, rashes, muscle aches, joint pain, cough, shortness of breath, coughing up blood and abdominal pain with food. Drugs profile discussed in this report include blisibimod, CCX-168, rituximab biosimilar, rituximab biosimilar1, rituximab biosimilar2, rituximab biosimilar3 and rituximab biosimilar4. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=269602. (This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases cover by this "Microscopic Polyangiitis (MPA) -- Pipeline Review, H1 2015" report include: Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis; Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA.

Table of content

List of Tables Number of Products under Development for Microscopic Polyangiitis (MPA), H1 2015 Number of Products under Development for Microscopic Polyangiitis (MPA) - Comparative Analysis, H1 2015 Number of Products under Development by Companies, H1 2015 Comparative Analysis by Late Stage Development, H1 2015 Comparative Analysis by Clinical Stage Development, H1 2015 Comparative Analysis by Early Stage Development, H1 2015 Products under Development by Companies, H1 2015 Microscopic Polyangiitis (MPA) - Pipeline by Anthera PharmaceuticalsAe Inc., H1 2015 Microscopic Polyangiitis (MPA) - Pipeline by Aprogen, Inc., H1 2015 Microscopic Polyangiitis (MPA) - Pipeline by ChemoCentryx, Inc., H1 2015 Microscopic Polyangiitis (MPA) - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 Microscopic Polyangiitis (MPA) - Pipeline by Hospira, Inc., H1 2015 Microscopic Polyangiitis (MPA) - Pipeline by Panacea Biotec Limited, H1 2015 Microscopic Polyangiitis (MPA) - Pipeline by Sandoz Inc., H1 2015 Assessment by Monotherapy Products, H1 2015 Number of Products by Stage and Target, H1 2015 Number of Products by Stage and Mechanism of Action, H1 2015 Number of Products by Stage and Route of Administration, H1 2015 Number of Products by Stage and Molecule Type, H1 2015 Microscopic Polyangiitis (MPA) Therapeutics - Recent Pipeline Updates, H1 2015 Microscopic Polyangiitis (MPA) - Dormant Projects, H1 2015

List of Figures Number of Products under Development for Microscopic Polyangiitis (MPA), H1 2015 Number of Products under Development for Microscopic Polyangiitis (MPA) - Comparative Analysis, H1 2015 Number of Products under Development by Companies, H1 2015 Comparative Analysis by Clinical Stage Development, H1 2015 Assessment by Monotherapy Products, H1 2015 Number of Products by Top 10 Targets, H1 2015 Number of Products by Stage and Top 10 Targets, H1 2015 Number of Products by Top 10 Mechanism of Actions, H1 2015 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 Number of Products by Top 10 Routes of Administration, H1 2015 Number of Products by Stage and Top 10 Routes of Administration, H1 2015 Number of Products by Top 10 Molecule Types, H1 2015 Number of Products by Stage and Top 10 Molecule Types, H1 2015

Explore more reports on Autoimmune Drugs Market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/autoimmune-drugs.

About Us:

RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers.

Media Contact: Ritesh Tiwari, RnR Market Research, +1888391544, sales@rnrmarketresearch.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE RnRMarketResearch.com
COPYRIGHT 2015 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 13, 2015
Words:933
Previous Article:Morningstar, Inc. Declares Regular Quarterly Dividend of 19 Cents Per Share.
Next Article:Arklu, Creators of Lottie(TM), a Unique Line of Alternative 'Pro-Girl' Dolls, Introduces Special Edition Gold Collection, New Dolls & Accessories at...
Topics:

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters